ERBB3 and malignant colon neoplasm: Specificity of anti-HER3 mAbs was examined by siRNA-based knockdown (KD) (Figure 2A) and CRIPR-Cas9/genome editing-mediated knockout (KO) (Figure 2B) of the HER3 gene in human colon cancer cells.